What's Happening?
Made Scientific and Basilard BioTech have announced a strategic partnership to advance the development of Basilard's Celletto™ platform, a nanomechanical gene delivery technology. This collaboration aims to improve the efficiency and scalability of gene delivery for T cell and induced pluripotent stem cell (iPSC) therapies. Celletto™ offers high transfection efficiency and cell viability, addressing limitations of viral and non-viral methods. The partnership will leverage Made Scientific's manufacturing capabilities to validate and scale the platform, with initial data expected by the end of Q3 2025.
Why It's Important?
This partnership represents a significant step forward in the field of gene therapy, potentially reducing costs and increasing the accessibility of advanced therapies. By improving gene delivery methods, the collaboration could accelerate the development of safer and more effective treatments for various diseases. The success of this initiative could have a broad impact on the biotechnology industry, enhancing the ability to produce cell-based therapies at a commercial scale.
What's Next?
The partnership will focus on validating and scaling the Celletto™ platform across various cell processes. Initial data readouts are expected by the end of Q3 2025, with results to be presented at upcoming industry conferences. This collaboration could lead to further advancements in gene delivery technologies, potentially setting new standards for the production of cell and gene therapies.
